Condition

HER2-low Hormone Receptor Positive Breast Cancer clinical trials and research

• 2Clinical trials
• 2Countries

All recruiting trials (2)

• AMXT 1501 and DFMO added to standard treatments for advanced breast cancer and melanoma

  This will test whether adding two oral drugs, AMXT 1501 and DFMO, to standard therapies helps people with advanced ER+ HER2- breast cancer or unresectable/metastatic melanoma.

  Recruiting at 20 sites Phase 1/2 Aminex Therapeutics, Inc. · Tucson, Arizona and 19 other locations · NCT07287917

• HLX22 plus trastuzumab deruxtecan for HER2-low, hormone receptor–positive advanced breast cancer

  This will test whether adding HLX22 to trastuzumab deruxtecan helps people with HER2-low, hormone receptor–positive advanced breast cancer who have progressed on or could not tolerate standard treatments.

  Recruiting Phase 2 Shanghai Henlius Biotech · Shanghai, Shanghai Municipality · NCT06832202

Related topics

Quick answers

How many HER2-low Hormone Receptor Positive Breast Cancer clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →